Upside Visualized on Eyegate Pharma (EYEG); Ascent Solar (ASTI) Skyrockets on Robust Sales Growth


Shares of Eyegate Pharmaceuticals, Inc. (Nasdaq:EYEG) soared 120% to touch the $3.74 mark in early trade Monday after analysts at Rodman & Renshaw initiated coverage on the company’s stock with a Buy rating and a price target of $10.00

EYEG stock is trading at $3.18, up $1.48 (or +$87.05%), and 5,665,461 of its shares exchanged hands so far

Eyegate Pharmaceuticals, which focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, has 7.66M Shares Outstanding and EYEG stock one-year range is from $1.38 to $27.00 per share



The price of Ascent Solar Technologies, Inc. (Nasdaq:ASTI) stock soared on Monday as the company said in its preliminary financial results that its fourth quarter 2015 revenue increased nearly 90% to $2.4 million versus the previous quarter, while full-year 2015 revenue surged approximately 23% to $6.5 million compared to 2014

ASTI stock is currently exchanging hands at $0.116, up $ 0.045 (or +63.38%), and 43,132,396 of its shares were traded so far, a large increase in activity versus its average volume (3m) of 9,844,390

Ascent Solar, a developer of thin-film photovoltaic modules, has 164.94M Shares Outstanding and ASTI stock 52-week range is between $0.06 and $2.08 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at